Country: Եվրոպական Միություն
language: անգլերեն
source: EMA (European Medicines Agency)
Mycoplasma hyopneumoniae, strain 7304 (Nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated
Laboratorios Hipra, S.A.
QI09AL08
Mycoplasma hyopneumoniae and porcine circovirus vaccine (inactivated, recombinant)
Pigs
Immunologicals for suidae, Inactivated viral and inactivated bacterial vaccines
For the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by Mycoplasma hyopneumoniae. Also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by Porcine circovirus type 2 (PCV2). Efficacy against PCV2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by Mycoplasma hyopneumoniae and/or PCV2 related diseases (as observed at 6 months of age in field studies).Mycoplasma hyopneumoniae: Onset of immunity: 3 weeks after vaccinationDuration of immunity: 23 weeks after vaccinationPorcine circovirus type 2:Onset of immunity: 2 weeks after vaccinationDuration of immunity: 22 weeks after vaccinationIn addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of PCV2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
Revision: 1
Authorised
2020-08-18
10 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Cardboard box with 1 PET vial of 50 doses (10 ml). Cardboard box with 1 PET vial of 100 doses (20 ml). Cardboard box with 1 PET vial of 125 doses (25 ml). Cardboard box with 1 PET vial of 250 doses (50 ml). 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MHYOSPHERE PCV ID emulsion for injection for pigs 2. STATEMENT OF ACTIVE SUBSTANCES Each dose of 0.2 ml contains: Inactivated recombinant _Mycoplasma hyopneumoniae_ _cpPCV2_ , strain Nexhyon: - _Mycoplasma hyopneumoniae ............................................... RP* ≥1.3 _ - _Porcine circovirus type_ _ 2_ ( _PCV2) capsid protein ............... RP* ≥1.3 _ * Relative Potency determined by ELISA. 3. PHARMACEUTICAL FORM Emulsion for injection. 4. PACKAGE SIZE 50 doses (10 ml) 100 doses (20 ml) 125 doses (25 ml) 250 doses (50 ml) 5. TARGET SPECIES Pigs. 6. INDICATION(S) 7. METHOD AND ROUTE(S) OF ADMINISTRATION Intradermal use. Read the package leaflet before use. 11 8. WITHDRAWAL PERIOD(S) Withdrawal period: Zero days. 9. SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use. Accidental injection is dangerous. 10. EXPIRY DATE EXP {month/year} Once opened use immediately. 11. SPECIAL STORAGE CONDITIONS Store and transport refrigerated. Do not freeze. Keep the container in the outer carton in order to protect from light. 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY Disposal: read package leaflet. 13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE For animal treatment only. To be supplied only on veterinary prescription. 14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN” Keep out of the sight and reach of children. 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Laboratorios Hipra, S.A. Avda. la Selva, 135 17170 Amer (Girona) SPAIN 16. MARKETING AUTHORISATION NUMBER(S) EU/2/20/259/001-004 12 17. MANUFACTURER’S BATCH NUMBER Batch {number} 13 MINIMUM read_full_document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MHYOSPHERE PCV ID emulsion for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 0.2 ml contains: ACTIVE SUBSTANCE: Inactivated recombinant _Mycoplasma hyopneumoniae_ _cpPCV2_ , strain Nexhyon: - _Mycoplasma hyopneumoniae ............................................... RP* ≥1.3 _ - _Porcine circovirus type_ _ 2_ ( _PCV2) capsid protein ............... RP* ≥1.3 _ _ _ * Relative Potency determined by ELISA. ADJUVANT: Light mineral oil ……. 42.40 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Emulsion for injection. White homogeneous emulsion after shaking. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunisation of pigs: - to reduce lung lesions associated with porcine enzootic pneumonia caused by _Mycoplasma _ _hyopneumoniae_ . Also, to reduce the incidence of these lesions (as observed in field studies). - to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by Porcine circovirus type 2 (PCV2). Efficacy against PCV2 genotypes a, b and d has been demonstrated in field studies. - to reduce culling rate and the loss of daily weight gain caused by _Mycoplasma hyopneumoniae _ and/or PCV2 related diseases (as observed at 6 months of age in field studies). _Mycoplasma hyopneumoniae: _ Onset of immunity: 3 weeks after vaccination. Duration of immunity: 23 weeks after vaccination. Porcine circovirus type 2: Onset of immunity: 2 weeks after vaccination. Duration of immunity: 22 weeks after vaccination. In addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of PCV2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination. 3 4.3 CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substance, to the adjuvant or to any of the excipients. 4.4 SPEC read_full_document